Koers Wayland Group Corp Canadian Securities Exchange
Aandelen
CA5667241007
Farmaceutische producten
Omzet 2016 | 4,06 5,59 3,81 | Omzet 2017 | 3,22 4,44 3,02 | Marktkapitalisatie | 203 mln. 280 mln. 190 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -8 mln. -11,02 mln. -7,5 mln. | Nettowinst (verlies) 2017 | -67 mln. -92,27 mln. -62,79 mln. | EV/omzet 2016 * | - |
Nettoschuld 2016 | 9,13 12,57 8,56 | Nettoliquiditeiten 2017 | 0,42 0,58 0,39 | EV/omzet 2017 | 63.046.727 x |
K/w-verhouding 2016 * |
-
| K/w-verhouding 2017 |
-2,13
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+39,33% | 6,11 mld. | |
-18,38% | 4,35 mld. | |
-9,17% | 3,18 mld. | |
+3,98% | 3,16 mld. | |
-3,41% | 2,51 mld. | |
+48,74% | 1,98 mld. | |
-4,82% | 1,74 mld. | |
-1,24% | 1,63 mld. | |
-8,96% | 1,6 mld. |